Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries.
de Jager VD, Timens W, Bayle A, Botling J, Brcic L, Büttner R, Fernandes MGO, Havel L, Hochmair MJ, Hofman P, Janssens A, Johansson M, van Kempen L, Kern I, Lopez-Rios F, Lüchtenborg M, Machado JC, Mohorcic K, Paz-Ares L, Popat S, Ryška A, Taniere P, Wolf J, Schuuring E, van der Wekken AJ. de Jager VD, et al. Among authors: janssens a. Lancet Reg Health Eur. 2024 Mar 1;38:100838. doi: 10.1016/j.lanepe.2024.100838. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38476742 Free PMC article. Review.
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer.
de Jager VD, Timens W, Bayle A, Botling J, Brcic L, Büttner R, Fernandes MGO, Havel L, Hochmair M, Hofman P, Janssens A, van Kempen L, Kern I, Machado JC, Mohorčič K, Popat S, Ryška A, Wolf J, Schuuring E, van der Wekken AJ. de Jager VD, et al. Among authors: janssens a. Lancet Reg Health Eur. 2024 Mar 1;38:100839. doi: 10.1016/j.lanepe.2024.100839. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38476751 Free PMC article. Review.
Perioperative Nivolumab in Resectable Lung Cancer.
Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, Ito H, Ciuleanu TE, de Oliveira Muniz Koch L, Janssens A, Alexandru A, Bohnet S, Moiseyenko FV, Gao Y, Watanabe Y, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Blum SI, Provencio Pulla M; CheckMate 77T Investigators. Cascone T, et al. Among authors: janssens a. N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926. N Engl J Med. 2024. PMID: 38749033 Clinical Trial.
Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.
Girard N, Ponce Aix S, Cedres S, Berghmans T, Burgers S, Toffart AC, Popat S, Janssens A, Gervais R, Hochstenbag M, Silva M, Burger IA, Prosch H, Stahel R, Xenophontos E, Pretzenbaher Y, Neven A, Peters S. Girard N, et al. Among authors: janssens a. ESMO Open. 2023 Jun;8(3):101576. doi: 10.1016/j.esmoop.2023.101576. Epub 2023 Jun 6. ESMO Open. 2023. PMID: 37285717 Free PMC article. Clinical Trial.
Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment.
de Groen RAL, de Groot FA, Böhringer S, Kret EJ, de Haan LM, Noordenbos T, Blommers S, Jansen REW, van Wezel T, van Eijk R, Raghoo R, Ruano D, Boome LT, Terpstra V, Levenga H, Ahsmann E, Posthuma EFM, Focke-Snieders I, Hardi L, den Hartog WCE, van den Berg A, Mutsaers P, Lam K, van der Poel MWM, Hamid MA, Woei-A-Jin FJSH, Janssens A, Tousseyn T, Bovée JVMG, Koens L, Diepstra A, Cleven AHG, Kersten MJ, Jansen PM, Veelken H, Nijland M, Dekker TJA, Vermaat JSP. de Groen RAL, et al. Among authors: janssens a. Blood Cancer J. 2025 Apr 29;15(1):82. doi: 10.1038/s41408-025-01291-z. Blood Cancer J. 2025. PMID: 40301298 Free PMC article.
Long term follow-up of MRD guided treatment of Ibrutinib plus Venetoclax for Relapsed CLL: phase 2 VISION/HO141 trial.
Niemann CU, Dubois J, Nasserinejad K, da Cunha-Bang C, Kersting S, Enggaard L, Veldhuis GJ, Mous R, Mellink CHM, van der Kevie-Kersemaekers AF, Dobber JA, Bjørn Poulsen C, Razawy W, Hollestein R, Frederiksen H, Janssens A, Schjødt I, Dompeling EC, Ranti J, Brieghel C, Mattsson M, Bellido M, Tran HTT, Kater AP, Levin MD. Niemann CU, et al. Among authors: janssens a. Blood Adv. 2025 Apr 18:bloodadvances.2024015180. doi: 10.1182/bloodadvances.2024015180. Online ahead of print. Blood Adv. 2025. PMID: 40249856
596 results